Reply to “No Robust Evidence of Lumefantrine Resistance”

Results from regular drug efficacy monitoring should always be interpreted in the context of the many limitations inherent to attributing apparent treatment failures to antimalarial resistance, as concisely summarized by [Hamed and Kuhen][1] ([1][2]). Notably, in study settings where direct

[1]  K. Kuhen,et al.  No Robust Evidence of Lumefantrine Resistance , 2015, Antimicrobial Agents and Chemotherapy.

[2]  N. Lucchi,et al.  Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Malaria in Children in Zaire and Uíge Provinces, Angola , 2014, Antimicrobial Agents and Chemotherapy.

[3]  Andreas Mårtensson,et al.  Plasmodium falciparum Drug Resistance Phenotype as Assessed by Patient Antimalarial Drug Levels and Its Association With pfmdr1 Polymorphisms , 2012, The Journal of infectious diseases.

[4]  Steven Edward Kern,et al.  The effect of food consumption on lumefantrine bioavailability in African children receiving artemether–lumefantrine crushed or dispersible tablets (Coartem®) for acute uncomplicated Plasmodium falciparum malaria , 2010, Tropical medicine & international health : TM & IH.

[5]  S. Meshnick,et al.  The perils of PCR: can we accurately 'correct' antimalarial trials? , 2010, Trends in parasitology.

[6]  K. Stepniewska,et al.  Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria , 2006, Malaria Journal.

[7]  S. Ward,et al.  Coartem (artemether-lumefantrine) in Africa: the beginning of the end? , 2005, The Journal of infectious diseases.

[8]  P. Rosenthal,et al.  Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. , 2005, The American journal of tropical medicine and hygiene.

[9]  F. Checchi,et al.  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial , 2005, The Lancet.

[10]  P. Phillips-Howard,et al.  The epidemiology of drug-resistant malaria. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.